Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Matthew Smith

Sports Medicine Guntersville, AL Doctor of Osteopathy

NPI 1336193440 CMS profile 151009

7938 Al Highway 69 Ste 100, Guntersville, AL 35976

Open in the dashboard

General payments

$72,524

31 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Matthew Smith of Guntersville, AL is reported in the CMS Open Payments database as having received $72,524 across 31 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $29,038 4
2023 General $33 1
2022 General $78 3
2020 General $32,528 2
2019 General $10,848 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Smith
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Matthew Smith were reported at $0. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Matthew Smith Sports Medicine median Middle half National median
2019 $10,848 $1,176 $199–$4,249 $163
2020 $32,528 $708 $96–$2,890 $114
2021 $0 $1,213 $152–$3,994 $132
2022 $78 $1,230 $159–$3,998 $149
2023 $33 $584 $146–$2,836 $160
2024 $29,038 $628 $163–$3,168 $164
2025 $0 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Stryker Corporation $61,509 3 payments
  2. Arthrex, Inc. $9,166 16 payments
  3. Prime Surgical, LLC $1,418 2 payments
  4. DePuy Synthes Sales Inc. $293 4 payments
  5. Zimmer Biomet Holdings, Inc. $49 1 payment
  6. Medtronic, Inc. $48 2 payments
  7. Olympus America Inc. $28 2 payments
  8. Bioventus LLC $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $61,404 2 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,075 3 payments
  3. Education $1,418 2 payments
  4. Food and Beverage $975 21 payments
  5. Travel and Lodging $652 3 payments
Products named General payments · program years 2019–2024
  1. PERFORMANCE SOLUTIONS $32,514 1 payment
  2. MAKO Knees, Hips $28,890 1 payment
  3. DELTA $145 1 payment
  4. MAKO Knees, Hips $105 1 payment
  5. Velys $90 1 payment
  6. Juggerknotless Soft Anchor $49 1 payment
  7. JuggerStitch $49 1 payment
  8. Tricera Handpiece $49 1 payment
  9. AQUAMANTYS(TM) $48 2 payments
  10. Olympus Integration Professional Services $14 1 payment
  11. Other $38 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

3,591

Median for Sports Medicine: 144

Drug cost

$23,401

Median for Sports Medicine: $1,027

Branded share of claims

16.8%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Daptomycin Generic 12 $5,830
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 420 $3,098
Ondansetron Hcl Generic 627 $2,818
Mupirocin Generic 290 $2,181
Oxycodone Hcl Generic 353 $1,635
Celecoxib Generic 85 $1,433
Tramadol Hcl Generic 510 $1,332
Meloxicam Generic 446 $1,194
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 159 $1,159
Gabapentin Generic 264 $872

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 132 billing codes

Paid by Medicare

$424,690

Of which drugs: $10,858

Medicare patients

856

Average age 75

Services billed

6,664

535 women, 321 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 32%
Ischemic heart disease 31%
Chronic kidney disease 29%
Depression 28%
Atrial fibrillation 21%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 18 1,312 $8,995
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 245 1,696 $1,159

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record